Cetuximab Plus P-HDFL for the First-line Treatment of Advanced Gastric Cancer
The investigators have initial evidence that the combination of cetuximab and cisplatin-HDFL may further improve the efficacy of the cisplatin-HDFL combination chemotherapy.
Gastric Cancer
DRUG: Cetuximab Plus P-HDFL
Confirmed objective response rates, Confirmed objective response within 4 weeks
Progression-free survival (PFS), overall survival (OS), treatment-related toxicity, 3 years and 5 years
The clinical efficacy (confirmed objective response rates, progression-free survival, overall survival), and treatment-related toxicities of this novel regimen will be examined as the first-line treatment in patients with nonresectable or recurrent/metastatic gastric cancer.